The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia

• Published in: Frontiers in oncology Vol. 11; p. 771669
• Main Authors: Nicolò, Antonella, Linder, Alexandra Theresa, Jumaa, Hassan, Maity, Palash Chandra
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21.12.2021
• Subjects: BCR signaling; biomarkers; CLL; immunoglobulin genes; Oncology; transformation; CLL; BCR signaling; transformation; biomarkers; immunoglobulin genes
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.771669

Advanced genome-wide association studies (GWAS) identified several transforming mutations in susceptible loci which are recognized as valuable prognostic markers in chronic lymphocytic leukemia (CLL) and B cell lymphoma (BCL). Alongside, robust genetic manipulations facilitated the generation of preclinical mouse models to validate mutations associated with poor prognosis and refractory B cell malignancies. Taken together, these studies identified new prognostic markers that could achieve characteristics of precision biomarkers for molecular diagnosis. On the contrary, the idea of augmented B cell antigen receptor (BCR) signaling as a transforming cue has somewhat receded despite the efficacy of Btk and Syk inhibitors. Recent studies from several research groups pointed out that acquired mutations in BCR components serve as faithful biomarkers, which become important for precision diagnostics and therapy, due to their relevant role in augmented BCR signaling and CLL pathogenesis. For example, we showed that expression of a single point mutated immunoglobulin light chain (LC) recombined through the variable gene segment IGLV3-21, named IGLV3-21 , marks severe CLL cases. In this perspective, we summarize the molecular mechanisms fine-tuning B cell transformation, focusing on immunoglobulin point mutations and recurrent mutations in tumor suppressors. We present a stochastic model for gain-of-autonomous BCR signaling and subsequent neoplastic transformation. Of note, additional mutational analyses on immunoglobulin heavy chain (HC) derived from non-subset #2 CLL IGLV3-21 cases endorses our perspective. Altogether, we propose a model of malignant transformation in which the augmented BCR signaling creates a conducive platform for the appearance of transforming mutations.